Occupancy remained at 66% despite seasonal headwinds and reduction in dialysis volumes.
Apollohosp Ltd — Q3 FY24
Apollo Hospitals reported a strong Q3 FY24 with consolidated revenue of INR 4,851 crore (+14% YoY) and EBITDA of INR 614 crore (+21% YoY).
✓ Verified against BSE filing
2-Minute Summary
Apollo Hospitals reported a strong Q3 FY24 with consolidated revenue of INR 4,851 crore (+14% YoY) and EBITDA of INR 614 crore (+21% YoY). PAT surged 56% YoY to INR 245 crore, driven by robust healthcare services growth (12% YoY) and a significant milestone: Apollo HealthCo achieved break-even a quarter early. Hospital occupancy stood at 66%, with ARPOB up 10% to INR 56,368. Management guided for 200 bps margin improvement in healthcare services over the next few quarters, supported by volume growth and cost rationalization. The 24/7 digital platform is expected to break even in 6-8 quarters, with new revenue streams like insurance distribution and digital therapeutics. A 2,000-bed expansion plan over four years is underway. Key risk: new bed additions may temporarily pressure margins if ramp-up is slower than expected.
अपोलो हॉस्पिटल्स ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कुल कमाई 4,851 करोड़ रुपये रही, जो पिछले साल से 14% ज्यादा है। कंपनी का मुनाफा 245 करोड़ रुपये रहा, जो 56% बढ़ा है। अस्पतालों में 66% बिस्तर भरे रहे और मरीजों से औसत कमाई 10% बढ़कर 56,368 रुपये हो गई। कंपनी की डिजिटल सेवा (अपोलो हेल्थको) ने उम्मीद से पहले ही घाटा खत्म कर लिया। आने वाले समय में कंपनी लागत घटाकर और मरीजों की संख्या बढ़ाकर मुनाफा और सुधारना चाहती है। साथ ही, अगले चार साल में 2,000 नए बिस्तर जोड़े जाएंगे। लेकिन सावधानी: नए बिस्तरों को भरने में देरी हुई तो मुनाफा कम हो सकता है।
Key Numbers
Average revenue per occupied bed increased 10% YoY, driven by pricing and case mix improvements.
Gross merchandise value of the digital platform grew 21% sequentially, with 2 million new users added.
Insurance revenues grew 16% YoY, now contributing 43% of total hospital IP revenue.
What Changed vs Last Quarter
Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%.
Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.
Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics.
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement.
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.
Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.
Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made.
Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.
Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.
Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24.
Mentioned in Q1 FY24, Q2 FY24
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
Management Guidance
Healthcare services revenue growth of 15% for FY24
Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%.
Management guidance revenue200 bps margin improvement in healthcare services over next few quarters
Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.
Management guidance marginsApollo 24/7 break-even in 6-8 quarters
Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics.
Management guidance growth2,000 beds over four years at INR 3,000 crore capex
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
Management guidance capexKey Risks
Margin pressure from new bed additions
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
medium · analyst_questionSeasonality and one-off events impacting growth
Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.
low · management_commentarySlowdown in 24/7 daily active users
Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.
medium · analyst_questionRegulatory risk from kidney racket allegations
Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made.
low · analyst_questionNotable Quotes
We have delivered ahead of time on a bit of break-even for Apollo HealthCo. I'm sure we will continue to deliver on our strategic intent.
Internally, we would like to believe that there is an opportunity to increase the margins by at least 200 basis points over the next few quarters.
Our entire growth is being led by volume. We are bullish that we'll be able to sustain at 20% kind of growth levels.
Frequently Asked Questions
What was Apollohosp's revenue in Q3 FY24?
Apollohosp reported revenue of ₹4,851 Cr in Q3 FY24, representing a +14% change compared to the same quarter last year.
What guidance did Apollohosp management give for FY25?
Healthcare services revenue growth of 15% for FY24: Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%. 200 bps margin improvement in healthcare services over next few quarters: Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization. Apollo 24/7 break-even in 6-8 quarters: Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics. 2,000 beds over four years at INR 3,000 crore capex: Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
What are the key risks for Apollohosp in FY25?
Key risks include Margin pressure from new bed additions — New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.; Seasonality and one-off events impacting growth — Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.; Slowdown in 24/7 daily active users — Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.; Regulatory risk from kidney racket allegations — Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made..
Did Apollohosp meet its previous quarter's guidance?
Of 1 tracked promise, management 0 met, 0 close, 1 missed.
Where can I read the full Apollohosp Q3 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.